Clinical significance of a CYP2D6 poor metabolizer - A patient with schizophrenia on risperidone treatment

Therapeutic Drug Monitoring

Volumn 30, Issue 6, 2008, Pages 748-751

  Božina, Nada ^a   Jovanović, Nikolina ^b   Lovrić, Mila ^a   Medved, Vesna ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

CYP2D6 genotype; Dextromethorphan; Risperidone; Schizophrenia

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; MULTIDRUG RESISTANCE PROTEIN 1; PALIPERIDONE; RISPERIDONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME SUBSTRATE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 57749116566     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181896afc     Document Type: Article

References (39)

1. Jansen PAJ, Niemegeers CJE, Awouters F, et al. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244:685-693.
2. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36:769-779.
3. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos. 1993;21:1134-1341.
4. Megens AA, Awouters FH, Schotte A, et al. Survey on pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology. 1994;114:9-23.
5. Huang ML, van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-268.
6. Scordo MG, Spina E, Facciol'a G, et al. Cytochrome P450 2D6 genotype and steady-state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999;147:300-305.
7. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9- hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn- Schmiederbergs Arch Pharmacol. 1999;359:147-151.
8. Bozina N, Granić P, Lalić Z, et al. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J. 2003;44:425-428.
9. Sachse C, Brockmoeller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
10. Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exper Ther. 1995;274:516-520.
11. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-169.
12. Cousein E, Barthelemy C, Poullain S, et al. P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2ATC7 model and an in vivo model. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:878-886.
13. Nakagami T, Yasui-Furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78:43-51.
14. Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol. 2005;20:493-500.
15. Aarnoudse AJ, Dieleman JP, Visser LE, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18:299-305.
16. Kirschbaum KM, Henken S, Hiemke C, et al. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res. 2008;188:298-303.
17. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
18. Siegmund W, Ludwig K, Giessmann T, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002;72:572-583.
19. Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
20. Stueven T, Griese EU, Kroemer HK, et al. Rapid detection of CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction. Pharmacogenetics. 1996;6:417-421.
21. Arjomand-Nahad F, Diefenbach K, Landt O, et al. Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid- modified hybridization probes. Anal Biochem. 2004;334:201-203.
22. Oselin K, Gerloff T, Mrozikiewicz PM, et al. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol. 2003;17:463-469.
23. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052.
24. Baumann P, Jonzier-Perey M. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chem Acta. 1988;171:211-222.
25. Bartoletti RA, Belpaire FM, Rosseel MT. High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction. J Pharm Biomed Anal. 1996;14:1281-1286.
26. Avenoso A, Facciola G, Salemi M, et al. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J Chromatogr B. 2000;746:173-181.
27. Titier K, Bouchet S, Pehourcq F, et al. High-performance liquid chromatographic method with diode array detection to identify and quantify atypical antipsychotics and haloperidol in plasma after overdose. J Chromatogr B. 2003;788:179-185.
28. Olesen OV, Licht RW, Thomsen, E et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380-384.
29. Nesvag R, Hendset M, Refsum H, et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114:21-26.
30. Balant-Gorgia AE, Gex-Fabry M, Genet C, et al. Therapeutic monitoring of risperidone using a new, rapid HPLC method: reappraisal of individual variability factors. Ther Drug Monit. 1999;21:105-115.
31. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78:520-528.
32. Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit. 2003;25:287-293.
33. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet. 2005;20:391-414.
34. Yasui-Furukori N, Mihara K, Takahata T et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol. 2004;57:569-575.
35. Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40:93-102.
36. Marier JF, Deschênes JL, Hage A, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 2005;77:2911-2926.
37. Wang JS, Zhu HJ, Markowitz J, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology. 2006;187: 415-423.
38. Weiss J, Dorman SM, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305:197-204.
39. Englund G, Hallberg P, Artursson P, et al. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med. 2004;2:8.